The duopoly of US pharmaceuticals firm Eli Lilly and Danish Novo Nordisk in the slimming drugs market is threatened. By August 7, 2024 Author: Post navigationPreviousPrevious post:Opposition leader, health minister spar over hospital conditionsNextNext post:‘We have run out of lobsters’
